{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027332","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2026-08-12T20:27:08+00:00","discovered_at":"2026-08-12T20:28:03.155663+00:00","generated_at":"2026-08-12T20:28:16.695523+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCardia Q2 net loss narrows to $1.6M; PMDA supports CardiAMP Japan filing","bullets":["Q2 2026 net loss $1.6M vs $2.0M year-ago; H1 loss $3.9M vs $4.8M.","R&D expense down to $0.9M from $1.4M; cash $4.1M, runway into 2027.","Raised ~$4.9M net proceeds from ATM facility in Q2.","Japan PMDA supports Shonin submission for CardiAMP; filing targeted Q4 2026.","FDA confirms CardiAMP HF II trial may support PMA; Helix DeNovo approval possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027332","json":"https://secwatch.observer/filing/0001437749-26-027332.json","markdown":"https://secwatch.observer/filing/0001437749-26-027332.md","text":"https://secwatch.observer/filing/0001437749-26-027332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/0001437749-26-027332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/bcda20260812_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:28:16.695523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}